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A computer model was developed to analyze the costs to 
Medicare and the potential procedure volume associated 
with alternative strategies for treatment of acute myocar- 
dial infarction. The expected cost per  case to Medicare for 
initial hospitalization was approximately $7,200 for conven- 
tional treatment, $7,900 for treatment with intravenous 
st:eptokinase and sS,4tlO for treatment with recombinant 
tissue-type plasmioogen activator (r&PA). The expt%tcd 
cost per case for use of streptokinase or &PA in combina- 
tion with cardiac catheterization performed either emer- 
gently or  at 48 h was in excess of $11JNJO. These cost 
estimates do not rellcct the cost of throtnbolytic drugs 
themselves because Medicare has not adjuqted its buspital 
Payment rates to take account of such costs. Although both 
streptokinase and r&PA will increase costs to Medicare for 
hospitalizations for acute myocardial infarction. both 
agents will do so at a reasonably low cost per  additional life 
saved-bctwecn SSO,OOO and $60,000. Emergency and 48 h 
catheterization strategies are considerably less cost-ef- 
fective. 
Regarding procedures, this model suggests that for 
every 1,000 patients treatment with streptokinase will re-  
sult in an additional 76 coronary angioplasty procedures 
and 26 coronary artery bypass operations, whereas treat- 
ment with rt-PA will result in an additional 122 angioplasty 
procedures and 43 bypass operations compared with cott- 
ventional trrPtmcttt. Thrumbolytk treatment is thus likely 
to htcrease sttbstantiPlly the volume of cardiac cathcterisa- 
tion, coronary “ngioplasty and corunary artery bypass 
surgery performed in the United States. 
(.I Am Coil Cardiol1988;12:58A-tWA) 
Estimates from the American Heart Association (I) suggest 
that approximately one million Americans are hospitalized 
each year as a result of acute myocardial infarction. Over the 
past several years, clinical management of many of these 
patients has undergone radical change, with increased use of 
thlombolytic drugs, such as streptokinase and recombinant 
tissue-type plasminogen activator (r&PA) (2-9). as well as 
aggressive use of coronary angioplasty and bypass surgery 
on either an emergent or urgent basis (IO.1 I). Recent clinical 
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trials (12) suggest that thrombolytic therapy might reduce the 
in-hospital mortality rate of patients with acute myocardial 
infarction by as much as 50%. 
In contrast to the tremendous attention being paid world- 
wide to the evaluation of the comparative efficacy of alter- 
native therapies for myocardial infarction, relatively little 
attention has been paid to either their comparative cost-ef- 
fectiveness or the capacity of our current health care system 
to provide alternative therapies on a large scale basis. One 
exception is the recent analysis performed by Laffel et al. 
(13). which estimated, from society’s perspective, the rela- 
tive cost-effectiveness of four primary treatments for acute 
infarction and three strategies for the prevention of reocclu- 
sion. In that analysis (13). the estimated increased cost per 
additional survivor compared with standard therapy ranged 
from $12,000 for treatment of a large infarction with intra- 
venous streptokinase within 2 h of the onset of symptoms to 
$1.8 million for treatment of a small infarction within 4 h of 
the onset of symptoms with intravenous r&PA plus coronary 
artery bypass surgery. 
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Figure 1. Clinical management algorithm (subtree) for conventional 
treatment strategy. CABG = coronary artery bypass graft surgery: 
Cath = catheterization; D/C = discharged; ETT = electrocardio- 
graphic exercise testing; PTCA = coronary angioplasly; Rx = 
treatment: w/in = within; w/o = without. 
Methods 
Structure OF d&ion model: treatmcat stratcgks. For 
each of the seven treatment strategies, we developed a 
clinical management algorithm t’krbtree”) that reflected 
pertinent diagnostic and therapeutic oprions and outcomes. 
These treatment strategy subtrees formed the basis of our 
decision analysis model. Our subtree for the conventional 
treatment strategy is shown in Figure I. For ctinventionally 
treated patients, we assumed that I) all patients with recur- 
rent ischemic myocardial pain would undergo cardiac cath- 
eterization, followed by coronary angioplasty, bypass sur- 
gery or medical treatment, depending on catheterization 
results; 2) some but not all patients without recurrent ische- 
mic myocardial pain would undergo predischarge exercise 
electrocardiographic (EC@ testing: 3) patients with a nep 
tive exercise test would be managed medically, whereas 
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Flgurc 2. Clincat management algo- 
rithm (subtree) for emergency and 48 h 
catheterization treatment strategies. 
SK = streptokinese: IPA = recombi- 
nant tissue-type plasminogen activa- 
tor: other abbreviations as in Figure I. 
patients with a positive exercise test would undergo cathe- 
terization. followed by coronary angioplasty or bypass sur- 
gery or medical treatment, depending on catheterization 
results; and 4) some but not all patients in whom attempted 
coronary angioplasty was unsuccessful would be referred for 
bypass surgery. Our conventional treatment strategy is 
consistent with the management strategy recently consid- 
ered to be the most cost-effective for asymptomatic postin- 
farction patients by the Cardiovascular Norms Committee of 
the American College of Cardiology (14). 
Tke SIFIICIII~~ of ortr srdmw jbr tire siteptokinusr und 
r&PA rredrrtrenr srrutegirs was the same as for conventional 
treatment cxccpt for inclusion of the possibility that throm- 
bolytic drug treatment might result in a bleeding complica- 
tion that was either fatal or severe enough to preclude the 
use of other diagnostic or therapeutic procedures in the 
management of myocardial infarction. 
Figure 2 presenrs the strucmre cflortr mergemy and 48 
h carkefrrircrrior~ slmlegirs (treccfrww strcr:qies 4 to 7). In 
these strategies, we assumed that the suusequent manage- 
ment of all patients who did clot suffer severe bleeding 
complications would be de:srmined by the coronary anat- 
omy visualized at catheterization. 
Data sources: clinical variables. We used three different 
sources of information to develop best, high and low esti- 
males for each clinical variable in our medcl. First. we 
performed a detailed review of studies published through the 
end of Gi. We used published data to estimate clinical 
variables whenever such data were available, Second, to 
obtain estimates for what we expected to be key variables 
for which published data were htcking, we sent a question- 
naire in late t98b to IS cardiologists--S who were university- 
based and involved in thrombolysis research, 5 who were 
university-based, but not involved in thrombolysis research 
and 5 who were nonuniversity-based and in private practice. 
By .A.pri! 1987, we received responses from 13 (87%) of these 
cardiologists (see Acknowledgments). We calculated the 
mean, median, trimmed mean (the mean after excluding the 
highest and lowest response) and Winsorized mean (the 
mean after replacing the highest and lowest responses with 
the next highest and next lowest responses) response for 
each variable addressed in our questionnaire. Because there 
was little difference in the vaiues derived from these different 
measures of ces!ral tendency, we used the ordinary mean as 
our best estimah~. We used the 75th and 25th percentile 
responses as our high and low estimates, respectively, of 
each variable estimated from our questionnaire responses. 
Finally, for variables for which we had no other data source, 
we used the consensus estimate of the two cardiologists on 
our research team (E.J.T. and A.D.G.). 
Assumptions: clinical variables. The best, high and low 
estimates that we employed for each clinical variable in our 
model, as well as the sources used for each estimate, are 
available from the authors upon written request. The key 
clinical assumptions that we employed are summarized in 
Table I and in the following discussion. 
Mortality rates. We assumed an in-hospital mortality rate 
of I I .3% for conventional treatment (25.8) and 10.0% for 
treatment with streptokinase. The latter estimate was de- 
rived by taking a weighted average of the mortality rate 
experienced by streptokinase-treated patients who pre- 
sented at 0 lo 3 and 3 to 6 h after the onset of symptoms 
in the Gruppo Italian0 per lo Studio della Streptochinasi 
nell’lnfarto Miocardico (GISSI) trial (2). Because we lacked 
JACC Vol. 12. No. 6 
December 1888: S8A-68A 
S U 3 N B E R G  ET AL. 6lA 
COST A N A L Y S I S  OF THROMBOLYTIC T H E R A P Y  
T&k 1. Key Assumptions: Clinical Variables 
SK + r&PA + SK + a-PA + 
Variablr Cow SK rt- ?A Em Calh Em Cmh 4X h Calh 48 h Cath 
In-hospital mortality rate (%) 
Pr (major CNS hemorrhage) 
R (Postinfarct angina) 
R (ET-0 
R (ElTt) 
R (PTCA) 
PlA 
No PIA 
R (CABG) 
PIA 
No PIA 
R (medical Rx) 
PIA 
No PIA 
R (FTCA successful) 
PIA 
No PIA 
II 3  10.0 93 
NA oGn2 0004 
0.16 0.23 0.28 
0.72 0 77 0 79 
0.33 0 36 0.38 
0 33 
!I 26 
0.26 0 24 0.24 
0.28 0 26 0.25 
041 0 27 0 23 
0.46 0.43 0 38 
0.89 
0.87 
0 47 0 53 
0’1 0 li 
0.89 
0.88 
0.38 
0.86 
100 9.3 100 9.3 
owz 0.004 O.OO? 0.004 
NA NA NA NA 
N A  NA NA NA 
N A  NA NA NA 
0 h5 0.62 0.56 0.48 
0 20 
0 I S  0.18 0.22 0.27 
0 88 
0.20 
0.86 
0.22 
0.88 
0.25 
0.88 
CABG = coronary artery bypass gsatl; CNS = central nervous system; Cow = conve4md lremmem (Ihal is, oo lhmmbolytic drug); Em Cath = emergency 
cardiac catheterization: ETT = exercise electrocardiography test: ElTt = posWe EX exerose tetl result; NA = oat spoliczbk: PIA = postinfarclioo ao&a. 
R = pobability: PTCA = coronary angioplasty: r&PA = recumbinam t~ssuc type plasminogen acrwalor: Rx = Ireatmcnt: SK = sIreptokioase: 48 h Cath = 
cardiac catheterization performed 48 h after admission. 
empiric data regarding the mortality rate associated with 
treatment with rt-PA, we derived an estimate for it by 
assuming that the probability of surviving acute myocardial 
infarction is a linear function of the probability of infarct- 
related artery patency immediately after initial treatment. 
Assuming that the probability of patency after initial treat- 
ment is 15% for conventional treatment (IS), 54% for strep 
tokinase (2,10,16-27) and 75% for r&PA (10.25-27). we 
interpolated an estimate of the in-hospital mortality rate with 
rt-PA treatment of 9.3%. We further assumed !ha! use of 
either emergency or 48 h catheterization on a routine basis in 
combination with streptokinase or rt-PA neither increased 
nor decreased patient mortality compared with the use of 
streptokinase or rt-PA alone (IO.1 I). 
Bleeding complications. We assumed that the probability 
of a major central nervous system hemorrhage was 0.2% 
with streptokinase (2,5,9) and 0.4% with r&PA (24). We 
further assumed that 50% of patients with a major central 
nervous system hemorrhage would die (5,23) and that the 
other 50% would not be considered candidates for coronary 
angioplasty o: bypass surgery. 
PosthSa&on angina. Our estimates of the incidence of 
postinfarction angina were derived from our survey of 
n:,.liologists and the published studies (2.8,283. Survey 
responses reflected a belief that postinfarction angina would 
occur more commonly with streptokinase than with conven- 
tional treatment, and more commonly after treatment with 
II-PA than with streptokinase. Presumably this belief was 
based on an assumption that there would be a higher vessel 
patency rate with rt-PA than with streptokinase and that it 
would be higher with stleptokinase than with conventional 
therapy and that this higher patency rate would be associ- 
ated with a reduced likelihood of completed infarction and 
an increased likelihood of subtotal stenoses and -esidual 
ischemic pain. 
Exerrix ele&-acardbgraphy. Our estimates of the pro- 
portion of patients without postinfarction angina who would 
undergo ECG exercise testing and the percent uf those 
patie,lts who wruld have a positive exercise test (C&at is, a 
:cs; result ihat was sutiiciintly abnormal to prompt cardiac 
catheterization) ‘were both derived from oer survey. Survey 
responses reflected the beliefs that the proportion of .Mients 
who would be able to undergo ECG exercise testing rnd the 
proportion of patients undergoing such testing whcs would 
have :1 positive test result wouid be higher with streptokinase 
than with conventional treatment and would be higher with 
r&PA than with streptokinase treatment. This belief presum- 
ably was based on reasoning similar to that described earlier. 
Cardii cathcter*ptioa. We assumed that ail patients 
with postinfarction angina and all patients with a positive 
ECG exercise test would undergo catheterization. On the 
basis of a recent review of published reports (221 and the 
opinions of our cardiologist coinvestigators, we assumed 
that 0.5% of patients with postinfarction angina who under- 
went catheterization and 0.1% of patients without postin- 
farction angina who underwent catheterization would die as 
a result of the catheterization. 
Coronary a ty vemia coronary artery bypass snr- 
gery versus me&al tmtmeat. Our estimates of the fre- 
quency with which patients would be treated with angio- 
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plasty or bypass surgery versus medical treatment alone 
under treatment strategies I to 3 were derived from our 
survey of cardiologists, and under treatment strategies 4 to 
7, these estimates were derived from the published reports 
and our cardiologist coinvcstigators. We assumed that a 
slightly higher proportion of patients would undergo bypass 
surgery if cathc*erization were routinely performed at 48 h 
rather than on an emergency basis because of the additional 
time physicians would have to reflect about optimal treat- 
men:. Our assumed tab: for rt-PA treatment is slightly higher 
than that for streprokinase treatment because of a presump 
tion that severe left ventricular dys unction would be present 
less frequently after rt-PA than .!fter streptokinase treat- 
ment. We also assumed that the probability that there would 
be no need for either angioplasty or bypass surgery would bc 
higher in patients treated with rt-PA than in those treated 
with streptokinase (as a result of the higher assumed throm- 
bolytic efficacy of r&PA) and would be higher for both 
treatments when catheterization was performed at 48 h 
rather than on an emergency basis (as a result of a higher 
patency rate at 48 h). 
Coronary nngloplasty. We assumed that 0. I% of patients 
undergoing angioplasty would have a fatal complication 
(16.29), that an additional 3% would have a complication that 
required emergency bypass surgery (20.29-32) and that 8% 
of the latter would die during bypass surgery (l&30,33-353. 
In addition, we assumed a 90% success rate for angioplasty 
performed on patent vessels, an 85% success rate for angio- 
plasty performed on vessels that remained occluded after 
conventional treatment or treatment with streptokinase and 
a 75% success rate for angioplasty performed on vessels that 
remained occluded after treatment with t-t-PA (26.36,37). 
Our assumption that tine angioplasiy success rate is Ivwcr for 
vessels that remain occluded after r&PA treatment is based 
‘n our cardiologist coinvcstigators’ experience that such 
vessels are more resistant to balloon angioplasty. We also 
assumed that patients with ~JStinfRrctiOR angina were more 
likely to have a patent infarct-related artery than were 
patients without postinfarction angina and that 80% of pa- 
tients in whom angioplasty was unsuccessful would undergo 
bypass surgery. 
Coronary artery bypass surgery. We assumed an opera- 
tive mortality rate of 7% for patients with postinfarction 
angina undergoing hypass surgery (17,19,21,38,39). 2% for 
patients without postinfarction angina undergoing bypass 
surgery (w3) and 8% for patients undergoing emergency 
bypass surgery as result of an angioplasty-related complica- 
tion (18.30.33-35). 
Bats sources and assumptions: costs. We estimated hos- 
pital payment rates by assuming that all procedures would be 
performed during the initial hospitalization for myocardial 
infarction and then assigning to each subtree branch the 
Diagnosis-Related Group (DRG) that Medicare would assign 
to patients managed according to that branch, For example, 
Tabk 2. Estimated Cost per  Case for Alternative Myoeardial 
Infarction Treatment Strategies 
DRG Professional 
Treatmem Stnde~y Rrmenl ($1 Fees ($1 Total ($)  
Conventional 5,867 I.361 7,278 
SK 6.312 I ,602 7,914 
n-PA 6.615 I.751 8.3643 
SK plus emergency 8,449 2,828 I I.277 
cathmrizarion 
SK plus 48 h a.643 2.788 Il.431 
cnlheierization 
rt-PA plus emergency 8,410 2.795 11,205 
catheterization 
CPA PiUS 48 h 8,871 2.795 II.666 
catheterization 
- - - -  
DRG = diagnosis-related group: other abbreviations as in Table I. 
because they underwent coronary angioplasty, patients man- 
aged according to the top branch of the conventional treat- 
ment strategy subtree would be assigned to DRG II2 (vas- 
cular procedures except major reconstruction). The five 
DRGs that we considered for patients hospitalized for acute 
myocardial infarction and the corresponding fiscal year 1988 
Medicare hospital payment rates for Baltimore metropolitan 
area hospitals that we employed for them (44) are listed in 
Table A of the Appendix. 
We estimated the professional fees associated with each 
sub/fee branch by assuming I) a $190 fee for a comprehen- 
sive admission history and physical examination, 2) a $55 fee 
for each subsequent day of daily care, 3) the length of a 
patient’s hospital stay was the arithmetic mean length of stay 
for the DRG to which they were assigned, and 4) physicians’ 
professional fees for cardiac catheterization, coronary angio- 
plasty and bypass surgery as shown in Table B of the 
Appendix. 
We did not consider either the cost of thrombolytic drugs 
or the potential effect cf thrombolytic treatment on patients’ 
lengths of stay in our cost estimates because neither of these 
factors allects current Medicare payment rates. 
Sensitivity analyses. The sensitivity of our results to the 
assumptions we employed was examined in both univariate 
and multivariate sensitivity analyses. In these analyses, we 
varied the estimated value of each variable across a range 
determined by our high and low estimates for that variable. 
All computations were performed using an IBM PC-AT 
nticrocornptuer supporting a decision analysis software pro- 
gram (SMLTREE) and a spreadsheet (LOTUS t-2-3). 
Results 
Total costs. Table 2 presents best evtimates of the aver- 
age DRG payment rate and professiona’ fees associated with 
treatment of patients with acute myocardial infarction ac- 
cording to each of the seven treatment strategies. Our model 
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Tabk 3. Incremental Cost-Effectiveness of Allernatwe Strategte\ 
for Treatment of Acute Myocardial lnfarct~on 
Tnatmenl Comparison 
SK ver~w conventional treatment 
ri-PA wsw conventional treatment 
II-PA versus SK 
ri-PA plus emergency cathrteriwlion 
versus conventional trealment 
rl-PA plus 48 h cathewrization verw 
conventional treatment 
SK plus emergency calhelerirzdmn 
verws conventional treatment 
SK plus 48 h catheterization versus 
convenfional treatment 
Incremental Cost per 
Add~lmnal Life Sdved’ III 
52.796 
56.Yno 
64.571 
198.9im 
??l.Ym 
311.462 
323.308 
‘Assumes a mortality rate of I I .3% for conventional treatment. IO 0% for 
streptokinase (SKI strategies and 9.3 .Z fc: n-PA stmte~er. Abbrevlatmns as 
in Table I. 
suggests that, on average, ireatment with streptokinase is 
approximately $700 more cosdy to Medicare than conven- 
tional treatment, whereas treatment with r&PA is approxi- 
mately $450 more costly than treatment with streptokinase, 
even without considering the cost CI thrombolytic drugs 
themselves. The expected cost to Medicare of each of thr 
four emergency and 48 h catheterization strategies is approx- 
imately $4,000 greater than that of conventional treatment. 
Cod per life saved. Our baseline assumptions regarding 
the mortalhy rate associated with each of the seven treat- 
ment strategies imply that, for every I.000 patients treated. 
all three streptokinase strategies would result in an addi- 
tional I3 lives saved compared with conventional treatment, 
whereas all three r&PA strategies would result in an addi- 
tional 20 lives saved compared with conventional treatment. 
On the basis of our estimates of the costs for each treatmem 
strategy (Table 2). Table 3 presents our best estimates of the 
incremental cost to Medicare per additional life saved for 
each treatment strategy compared with conventional treat- 
ment and for &PA versus streptokinase. 
Tmbk 4. Estimated Procedure Volume (per  I.UOb patientt) 
Treaimenl Strategy Cath FTCA CABG 
Conventional 322 94 Yx 
SK 420 170 124 
r&PA 472 ?I6 141 
SK plus emer~egency Y6x 626 226 
catheternation 
SK plus 48 h 947 52s 253 
cardiologic su&ey responses that influence these estimates 
ca!belerizalion consistently reflected the belief that the probability of 
r&PA plus emergcscy Y64l MI 226 postinfarction angina, the proportion of patients that would 
catheteriration be able to undergo ECG exercise testing and the proportion 
II-PA plus 48 h 951 4Sl 278 of patients undergoing ECG exercise testing who would have 
catheterization a positive test result would be higher for streptokinase than 
Abbrevinllons ar  in Table I. for conventional treatment and would be highe: for rt-PA 
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COST P E R  C & S E  N U M B E R  OF CATHI ;  
IO  
f  
I  
* 
B  
1: 
8: 
N U M B E R  OF PTCA’S N U M B E R  OF C A B C S  
300 r.Qo 
iz 
;  180 
g 180 
c 
f  
too 
‘b loo I3 
80 
84 
% 
0 Low 0 Low 
Figure 3. Sensitivity of estimates of cost per case and procedure 
volumes to simultaneous variation in the estimates for three <aria- 
bles: probability of postinfarction angina, probability of undergoing 
exercise tolerance testing and Probability of exercise tolerance test 
results being positive. Rest = model projection using our best 
estimate for each of the three variables simultaneously; conven- 
tional = conventional treatment; high = model projection using our 
highest estimate for each of the three variables simultaneously; low 
= model projection using our lowest estimate for each of the three 
variables simultaneously; SK = intravenous treptokinase; TPA = 
intravenous recombinant tissue-type plasminogen actiwtor. 
than for streptokinase, regardless of the exact estimate for 
each of these three variables. Relaxation of this assumption 
narrows the differences between strategies in the estimates 
of the cost per case and procedure volumes (analysis not 
shown). 
Because DRG payment rates for patients with acute 
myocardidl infarction vary depending on whether bypass 
surgery, angioplasty or medical treatment alone is prcvided, 
our estimates of the cost per case for each of the seven 
treatment strategies vary as our estimate of the proportion of 
patients undergoing either bypass surgery or angioplasty 
changes. So, too, of course, does our estimate of the number 
of each !ype of procedure performed under each of the seven 
treatment strategies (Table 5). The estimated cost to Medi- 
care per patient treated can be nearly $1,898 higher in 
institutions that aggressively provide bypass surgery com- 
pared with those that tend to perform bypass surgery on 
patients less aggressively. Table 5 also demonstrates the 
marked variation in the frequency zvith which coronary 
angioplasty and bypass surgery could be provided under any 
given treatment strategy. 
Finally, becaase recent data (12) suggest that mortality 
rates associated with thrombolytic treatment may be lower 
than those we employed in our primary analyses, we ex- 
plored the sensitivity of our major dependent variables, (cost 
per case, cost-effectiveness and procedure volumes) to as- 
sumed mortality rates. A comparison of results assuming an 
rt-PA treatment mortality rate of 5 versus 9.3% (Table 6) 
illustrates the effect of our mortality rate assumption. This 
analysis demonstrates that neither estimated cost per case 
nor estimated volume of cardiac catheterizations, angio- 
plasty procedures or bypass operations changes consider- 
ably over a broad range of mortality rates. In contrast, the 
estimated cost per additional life saved with thrombolytic 
therapy compared with conventional treatment decreases 
substantially as the mortality rate associated with throm- 
bolytic treatment decreases. 
Discussion 
The efficacy of thrombolyiic iherapy in reducing the 
mortality rate from acute myocardial infarction has gener- 
ated extraordinary excitement within the medical profession 
and the public at large. As the medical profession focuses its 
efforts on defining which of the currently available treatment 
alternatives is the most efficacious and on the development 
of new treatment strategies, attention must also be given to 
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Table 5. Sensitivity of Estimates of Co\t per  Case an+! Proctdure Volumes to Assumptions 
Regarding the Proportion of Patients Urdergomg Surgery Versus Aagjoplasty Versus hledical 
Treatment After Cardiac Catheterization - --- 
Pmcedure Volume (per I.wO parrents 
treated) 
Co5tiCar: 151 FTCA 
-___. ~ 
Hrsh 14w HO Low 
Treatsent strategy 
Conventional X.176 6,522 131 40 
SK 8.439 7.240 248 IO5 
r&PA 8.9:3 7.705 28% 147 
SK plus catheternation emergency 12.089 10.3oa 675 578 
SK plus 48 h catheterizatton 12.219 w.453 568 473 
u-PA plus cathetenraaon emergen y 12.018 10.239 644 548 
n-PA slus 48 h cathetenzatron 12.456 III.677 494 399 
High = high es,imate: Low = low estimate: other abbrevntlons as m Table I. 
CABG - 
HisIr Low 
155 53 
I55 83 
172 IO43 
275 176 
3w 202 
275 176 
325 226 
the costs of alternative !rtarment strategies and to the 
facilities that would be required to perform the cardiac 
catheterizations, angioplasty procedures and bypass opera- 
tions that would likely be generated by alternative treatment 
strategies. 
Cesfs per case. Our analysis suggests that when costs are 
estimated from the perspective of Medicare, treatment strat- 
egies involving the use of either streptokinase or r&PA 
alone, even though they are more expensive ihan conven- 
tional traalment, result in additional lives being saved at a 
cost that IS reasonably low and compares favorably with the 
increased cost per additional life saved associated with other 
common medical practices, such as renal dialysis ($54,000 
[I983 dollars] per quality adjusted life year gained) (45) and 
treatment of a cholesterol level of 315 mg/dl in men ~50 
years of age ($56,000 to $69,OtNJ [1987 dollars] per year of lift 
gained) (46). In contrast, routine performance of emergency 
or 48 h cardiac catheterization in combination with use of 
streptokinase or rt-PA is considerably more expensive. 
Tahk 6. Estimated Cost per Case, Cost-Effectiveness and 
Procedure Volumes Associated With Treatment With r&PA 
Given Different Assumptions Regarding Effect of rt-PA o,. 
In-Hospital Mortality 
Variable 
R-PA Mortality 
Rate = 9.3% 
R-PA Mortahty 
Rate = 5% 
cost per  ease 
Increased cost per  additiona! !ifc 
saved compared with 
conventional treatment 
Procedure volume (per  I,ONl 
patients reated) 
Cardiac catheterization 
F’TCA 
CABG 
Abbreviations a  in Table I. 
6 8.366 0 8.461 
556.7% Sl9.U 
472 484 
216 221 
141 145 
Given our assumptior that the use of emergency 48 h 
catheterization on a routine basis does not improve the 
short-term survival rate, these strategies are also less cost- 
effective than the use of streptokinase or &PA alone. 
It is important to emphasize that our cost estimates reflect 
expected CC~?P to Medicarc under the current DRG-based 
prospective payment system, rather than actual resource 
costs incurred by hospital providers or society. Our analysis 
demonstrates that under this payment system, the costs to 
Medicare of alternative strategies for treatment of acute 
myocardial infarction are determined by the extent to which 
each treatment alternative shifts patients out of DRGs ex- 
plicitly established for patients with myocardial infarction 
(DRGs 121, 122 and 123) and into higher paying DRGs 
associated with performance of bypdss surgery (DRG 106) or 
angioplasty (DRG 112). Our model’s suggestion that treat- 
ment with &PA is more costly to Medicare than is treatment 
with streptokinase is thus due to a series of assumptions *hat 
result in a higher projected rate of angioplasty and bypass 
surgery after treatment with r&PA compared with streptoki- 
nase. These assmnptions reflect beliefs that r&PA has a 
higher thrombolytic efficacy than streptokinase, which, in 
turn, will reduce mortality but inrrease the proportion of 
patients with residual ischemia. Simdarly, our model’s sug- 
gestion that 48 h catheterization strategies are more expen- 
sive than emergency catheterization strategies is a result of 
our assumption that more patients will undergo bypass 
surgery if treatment decisions are based on the results of 
catheterization performed at 48 h rather than on an emer- 
gency basis as a result of the additional time physicians 
would have to reflect on optimal treatment. Additional 
experience is required to know whether, in fact, such 
assumptions are valid. 
A! least for now. Medicare has decided noi to a&m 
DRG payment rates to take account of the cost of lrom- 
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bolyric drugs (47). Because our cost analysis was performed 
from Medicare’s perspective, our cost estimates do not 
reflect the cost of these drugs. If Medicare decides to 
reimburse hospitals for the cost of these drugs outside of the 
DRG payment sys:em, then our estimates of the cost of 
streptokinase strategies would increase by approximately 
$200 per case and our estimates of the cos! of II-PA 
strategies would increase by approximately $2,200 per case. 
Over the longer term, DRG payment rates will be adjusted to 
reflect not only the cost of thrombolytic drugs, but also the 
effect of thrombolytic drugs on patients’ lengths of stay and 
resource use during hospitalization. 
Even without an explicit decision by Medicare to adjust 
DRC payment rates, Medicare could become liable for the 
cost of thrombolytic drugs under certain circumstances. For 
example, if it were feasible and safe to administer throm- 
bolytic drugs in an ambulance on route to the hospital, under 
current payment rules, the cost 6: thtontbolytic drugs would 
be ccvered under Part B of Medicare, and hence would be 
paid outside of the DRG system. (Part B of Medicare covers 
professional fees and cell&t other services.) The cost of 
thrombolytic drugs is also curently paid for under Part B of 
Medicare when the drugs are admk;steted in the emergency 
room of a hospital to a patient who is subsequently trans- 
ferred to another hospital, rather than being admitted to the 
hospital that administers the drug. Whether ivieoicare wil! 
continue to pay for thrombolytic drugs under this circum- 
stance is unclear. 
Despite our use of considerably different methodologies, 
our cost estimates and conclusions arc remarkably consis- 
tent with those of another recently published analysis (13) of 
the cost-effectiveness of thrombolytic therapy for acute 
myocardial infarction. Whereas Laffel et al. (13) estimated 
the cost-effectiveness of alternative treatment strategies 
within numerous patient subgroups (for example, patients 
.with a small versus moderate versus a large infarction who 
presented within 2 versus 4 versus 6 h of the onset of 
symptoms) from the perspective of society, we developed 
estimates of the average mortality rates and costs associated 
with alternative treatment strategies based on the results of 
published clinical trials. Our assumption of an 11.3% mor- 
tality rate for conventional treatment corresponds roughly to 
the I?% in-hospital mortality rate Laffel et al. (13) assumed 
for patirots Wit!! a  modera:c-sized ii&i&n. Our estimates 
of approximately $53,000 and $57,tlOtl for the incremental 
cost per additional life saved for treatment with etreptoki- 
nase and rt-PA, respectively, compared with conventional 
treatment are comparable to the estimates of Laffel et al. (13) 
of $59,009 and %65,0&l for the marginal cost per additional 
life saved for treatment of a moderate-sized myocardial 
infarction within 2 h after the onset of symptoms with 
intravenous streptokinase aad iotravenous r&PA, respec- 
tively, compared with conventional treatment. In addition, 
Our estimates of the incremenlal cost per addiiiondl life 
saved for streptokinase or rt.PA in combination with emer- 
gency catheterization ($311,462 and $198.9CtO, respectively) 
are similar to those of Laffet et al. 113) of the marginal 
cost-effectiveness of similar strategies performed on patients 
presenting within 4 h of the onset of symptoms ($268,000 and 
$235.000, respectively). 
Aggregate costs. The overall impact of thromholytic ther- 
apy on the costs of treatment of patients with acute myocar- 
dial infarction will depend on the number of patients who 
receive thrombolytic treatment. If one estimates, as the 
Prospective Payment Assessment Commission (unpublished 
data) has, that approximately 275,000 Medicare beneficiaries 
are hospitalized each year for acute myocardial infarction, it 
is likely that no more than 100,000 Medicare beneficiaries 
would receive thrombolytic therapy annually given current 
inclinations not to give thrombolytic drugs to most patients 
who are 275 years of age or who have a non-Q wave 
infarction (2&t). If tOO,OtlO Medicare heneticiaries were to 
be eligible for thromholytic therapy each year, then our 
model suggests that the use of streptokinase would increase 
Medicare costs by $70 million per year, whereas the use of 
+PA would increase Medicare costs by $114 million per 
year. Emergency and 48 h catheterization strategies would 
increase the cost to Medicare of treating 100,000 beneficia- 
ries by $285 million to $350 million pr year. 
Procedure vohmte. Our analysis atso suggests that throm- 
holytic therapy wtii markedly increase the volume of cardiac 
catheterizations, coronary angioplasty procedures and cor- 
onary artery bypass operations that are performed in this 
country. Industry analysts have estimated that 175,BOtl cor- 
onary angioplasty procedures are performed each year in the 
United States (49). and that the number of patients that 
would be considered eligible for thrombolytic treatment in 
the United States could he as high as 300,000 per year (50). 
Our model suggests that treatment of 300,000 patients with 
acute myocardial infarction annually with rt-PA rather than 
conventional treatment would increase the annual number of 
coronary angioplasty procedures performed in the United 
States by 36.600 (21%), ignoring any effect of the use of 
rt-PA on the use of coronary angioplasty during the first or 
subsequent years after initial treatment for infarctions. Were 
facilities avaihtble to provide them, treatment of 3OO.OOtJ 
patients with streptokinase plus routine use of emergency 
cardiac catheterization would increase the annual volume of 
coronary angioplasty procedures by 159,000 (91% of the 
total number of coronary angioplasty procedures currently 
performed annually in the United States). 
Limitations of study. Two important limitations of our 
analysis should be underscored. First, sensitivity analyses 
demonstrated that our conclusions regarding the costs per 
case and orocedure volumes are most sensitive to variables 
in our model, the values of which were estimated from our 
survey of cardiologists, rather than from published clinical 
studies. Our analysis of low and high as wel! as best 
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estimates for these variables in our sensitivity analyses 
lessens the impact of this limitation by providing reasonable 
ranges for our estimates of outcome variables of interest. 
Our analysis demonstrates, however, that the impact of 
thrombolytic therapy on the frequency with which patients 
develop postinfarction angina and manifest a positive ECG 
exercise test will be an important determinant of the cost and 
procedure volume implications of thrombolytic therapy. 
Empiric data regarding these phenomena should, therefore, 
be collected. 
Finally, in our malysis, we assessed both costs and 
outcomes from a short-term rather than a long-term perspec- 
tive. Although recent data (5132) suggest that the decrease 
in the in-hospital mortality rate achievable with thrombolytic 
therapy is maintained over the year after acute myocardial 
infarction, additional research is needed to clarify the 
amount and types of resources consumed over an extended 
period by patients treated under alternative strategies. Ulti- 
mately, conclusions regarding the relative costs, procedure 
volume implications ar 7st-effectiveness of alternative 
treatment strategies should be based more on these long- 
term than on short-term outcomes. 
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